Non-viral carriers for nucleic acids delivery: Fundamentals and current applications

S Shtykalova, D Deviatkin, S Freund, A Egorova… - Life, 2023 - mdpi.com
Simple Summary Gene therapy is one of the most promising approaches to treating various
inherited and acquired diseases by delivering genetic constructs into the cells and tissues of …

Exploring the role of peptides in polymer-based gene delivery

Y Sun, Z Yang, C Wang, T Yang, C Cai, X Zhao… - Acta Biomaterialia, 2017 - Elsevier
Polymers are widely studied as non-viral gene vectors because of their strong DNA binding
ability, capacity to carry large payload, flexibility of chemical modifications, low …

Serum-Resistant Ternary DNA Polyplexes for Suicide Gene Therapy of Uterine Leiomyoma

A Egorova, S Shtykalova, M Maretina, S Freund… - International Journal of …, 2023 - mdpi.com
Uterine leiomyoma (UL) is a prevalent benign tumor in women that frequently gives rise to a
multitude of reproductive complications. The use of suicide gene therapy has been …

Polycondensed peptide carriers modified with cyclic RGD ligand for targeted suicide gene delivery to uterine fibroid cells

A Egorova, S Shtykalova, M Maretina, A Selutin… - International Journal of …, 2022 - mdpi.com
Suicide gene therapy was suggested as a possible strategy for the treatment of uterine
fibroids (UFs), which are the most common benign tumors inwomen of reproductive age. For …

Oligohistidine and targeting peptide functionalized TAT-NLS for enhancing cellular uptake and promoting angiogenesis in vivo

Q Li, X Hao, SSA Zaidi, J Guo, X Ren, C Shi… - Journal of …, 2018 - Springer
Background Gene therapy has been developed and used in medical treatment for many
years, especially for the enhancement of endothelialization and angiogenesis. But slow …

Peptide-Based Nanoparticles for αvβ3 Integrin-Targeted DNA Delivery to Cancer and Uterine Leiomyoma Cells

A Egorova, A Selutin, M Maretina, S Selkov, A Kiselev - Molecules, 2022 - mdpi.com
Uterine leiomyoma is the most common benign tumor of the reproductive system. Current
therapeutic options do not simultaneously meet the requirements of long-term efficiency and …

iRGD-Targeted Peptide Nanoparticles for Anti-Angiogenic RNAi-Based Therapy of Endometriosis

A Egorova, M Petrosyan, M Maretina, E Bazian… - Pharmaceutics, 2023 - mdpi.com
Anti-angiogenic RNAi-based therapy can be considered as a possible strategy for the
treatment of endometriosis (EM), which is the most common gynecological disease …

CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery

A Egorova, A Shubina, D Sokolov, S Selkov… - International journal of …, 2016 - Elsevier
The application of small interfering RNA (siRNA) for specific gene inhibition is a promising
strategy in gene therapy treatments. The efficient cellular delivery of therapeutic siRNA is a …

Characterization of iRGD-ligand modified arginine-histidine-rich peptides for nucleic acid therapeutics delivery to αvβ3 integrin-expressing cancer cells

A Egorova, A Selutin, M Maretina, S Selkov, V Baranov… - Pharmaceuticals, 2020 - mdpi.com
Efficient and specific delivery of nucleic acid (NA) therapeutics to tumor cells is extremely
important for cancer gene therapy. Various therapeutic strategies include delivery of DNA …

Anti-angiogenic treatment of endometriosis via anti-VEGFA siRNA delivery by means of peptide-based carrier in a rat subcutaneous model

A Egorova, M Petrosyan, M Maretina, N Balashova… - Gene Therapy, 2018 - nature.com
Abstract Development of gene therapy for endometriosis requires inhibition of
vascularization in endometrial lesions. We have previously developed CXCR4 receptor …